323 related articles for article (PubMed ID: 34194397)
1. Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.
Song A; Kim SJ; Kim MS; Kim J; Kim I; Bae GY; Seo E; Cho YS; Choi JY; Cho SY; Jin DK
Front Endocrinol (Lausanne); 2021; 12():687834. PubMed ID: 34194397
[TBL] [Abstract][Full Text] [Related]
2. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the medical treatment of Graves' disease (GD)].
Peixoto MC; Coeli CM; Vaisman M
Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
5. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of anti-thyroid drug treatment in childhood-onset Graves' disease.
Puttawong D; Mahachoklertwattana P; Numthavaj P; Woratanarat P; Pongratanakul S; Koad P; Poomthavorn P
Clin Endocrinol (Oxf); 2023 Jun; 98(6):823-831. PubMed ID: 36562146
[TBL] [Abstract][Full Text] [Related]
7. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome of Graves' disease in Thai children.
Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
[TBL] [Abstract][Full Text] [Related]
9. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome.
Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y
J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520
[TBL] [Abstract][Full Text] [Related]
10. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
11. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
Vigone MC; Peroni E; Di Frenna M; Mora S; Barera G; Weber G
J Endocrinol Invest; 2020 May; 43(5):595-600. PubMed ID: 31713721
[TBL] [Abstract][Full Text] [Related]
12. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
13. Management of thyrotoxicosis in children and adolescents: 35 years' experience in 304 patients.
Azizi F; Amouzegar A
J Pediatr Endocrinol Metab; 2018 Jan; 31(2):159-165. PubMed ID: 29306930
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
[TBL] [Abstract][Full Text] [Related]
15. Antithyroid drug therapy for Graves' hyperthyroidism: is long-term administration of a small maintenance dose necessary?
Tajiri J; Noguchi S; Morita M; Tamaru M; Murakami N
Endocrinol Jpn; 1991 Apr; 38(2):223-7. PubMed ID: 1684322
[TBL] [Abstract][Full Text] [Related]
16. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
18. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
Liu X; Shi B; Li H
Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
[TBL] [Abstract][Full Text] [Related]
19. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
[TBL] [Abstract][Full Text] [Related]
20. Graves' disease in children: long-term outcomes of medical therapy.
Rabon S; Burton AM; White PC
Clin Endocrinol (Oxf); 2016 Oct; 85(4):632-5. PubMed ID: 27169644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
